Straits Times Index
3,330.09 +11.64 (+0.35%) S&P 500
5,284.51 -20.21 (-0.38%) Dow
38,737.05 -332.54 (-0.85%) Nasdaq
16,929.86 +9.07 (+0.05%) Bitcoin USD
67,505.09 -2,347.93 (-3.36%) CMC Crypto 200
1,472.26 -24.20 (-1.62%)
MRK Sep 2024 135.000 call
| Previous close | 3.4500 |
| Open | 3.0500 |
| Bid | 2.1800 |
| Ask | 2.2900 |
| Strike | 135.00 |
| Expiry date | 2024-09-20 |
| Day's range | 2.1200 - 3.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 5.8k |
BenzingaMerck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.
Simply Wall St.Is Merck & Co., Inc.'s (NYSE:MRK) Recent Performance Underpinned By Weak Financials?
Merck (NYSE:MRK) has had a rough month with its share price down 1.3%. To decide if this trend could continue, we...
Business WireMerck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
RAHWAY, N.J., May 28, 2024--Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer
